Clinical trials: Thromboangiitis Obliterans
Critical Limb Ischemia Due to Buerger's Disease
A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease
This study is being conducted as an extension of the phase II clinical trial SRPL/CLI/10-11/001 (NCT01484574). The CDSCO has recommended flexibility for continued clinical study in consultation with ICMR, as per recommendation of…
- Trial name
- NCT03056742
- Testing
- Stempeucel(R)
- Where
- 8 sites in India
- Sponsor
- Stempeutics Research Pvt Ltd
Peripheral Arterial Disease(PAD), Arterial Occlusive Disease
Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
The goal of this observational study is to learn about the long-term effects of Donaperminogene Seltoplasmid Injection (NL003) in participants who have been received drug NL003 or placebo at least one dose from the parent phase…
- Conditions
- Peripheral Arterial Disease(PAD), Arterial Occlusive Disease, Arteriosclerosis Obliterans, Thromboangiitis Obliterans
- Trial name
- NCT07023965
- Testing
- NL003
- Where
- 5 sites in China
- Volunteers
- 542 people
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
Critical Limb Ischemia, Buerger's Disease
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to Buerger's…
- Trial name
- NCT05854615
- Testing
- Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells
- Where
- Malaysia
- Volunteers
- 3 people
- Sponsor
- Cell Biopeutics Resources Sdn Bhd
Critical Limb Ischemia
Autologous Endothelial Progenitor Cells (EPCs) From Peripheral Blood in the Treatment of Critical Limb Ischemia
Aim: to value the safety and efficacy of local intramuscular administration of immunoselected autologous endothelial progenitor cells in the treatment of critical limb ischemia in patients without revascularization options.
- Trial name
- NCT01595776
- Testing
- Endothelial progenitor cells intramuscular implant
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Buerger's Disease
Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease
The purpose of this study is to investigate the efficacy and safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with Buerger's disease.
- Trial name
- NCT01302015
- Testing
- RNL-Vascostem®
- Where
- 2 sites in South Korea
- Volunteers
- 15 people
- Sponsor
- R-Bio
Thromboangiitis Obliterans, Arteritis
Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia
To compare the efficacy and cost-effectiveness between purified CD34+ cells and peripheral blood mononuclear cells in treatment of critical limb ischemia
- Conditions
- Thromboangiitis Obliterans, Arteritis, Peripheral Arterial Disease
- Trial name
- NCT02089828
- Testing
- autologous purified CD34+ cells, autologous peripheral blood mononuclear cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Non-healing Wound, Thromboangiitis Obliterans
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.
- Trial name
- NCT04914247
- Testing
- Selexipag
- Sponsor
- Actelion
Critical Limb Ischemia, Peripheral Arterial Disease
Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia
Using autologous bone marrow mononuclear cells (BM-MNC) to treat patients with chronic limb ischemia has been proved safe and effective.
- Conditions
- Critical Limb Ischemia, Peripheral Arterial Disease, Buerger's Disease
- Trial name
- NCT01446055
- Testing
- ResQ processed bone marrow sample, Ficoll conventional cell processing method
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xuanwu Hospital, Beijing
Critical Limb Ischemia, Peripheral Arterial Disease - PAD
Autologous Fat Grafting in the Treatment of Critical Limb Ischaemia
Critical Limb Ischaemia (CLI) is a condition characterized by chronic ischemic at-rest pain, ulcers, or gangrene for more than 2 weeks in one or both legs, attributable to objectively proven arterial occlusive disease.CLI is…
- Conditions
- Critical Limb Ischemia, Peripheral Arterial Disease - PAD, Ischemic Ulcer, Ischemic Feet
- Trial name
- NCT04746599
- Testing
- Autologous Fat Grafting
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Critical Limb Ischemia, Arteriosclerosis Obliterans
Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia
Adipose-derived regenerative cells (ADRC) will be extracted from lipoaspirate by enzymatic digestion. 10 mL of autologous ADRC suspension injected intramuscularly, close to the site of muscle injury.
- Conditions
- Critical Limb Ischemia, Arteriosclerosis Obliterans, Peripheral Arterial Disease, Thromboangiitis Obliterans
- Trial name
- NCT02864654
- Testing
- ADRC injection, ADRC isolation, Liposuction
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc
Buerger Disease, Arteriosclerosis Obliterans
TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation
Clinical studies have established that implantation of bone marrow mononuclear cells (BM-MNCs) or peripheral blood mononuclear cells (PB-MNCs) into ischaemic limbs increases collateral vessel formation.
- Trial name
- NCT00145262
- Testing
- Autologous Bone Marrow Mononuclear Cell Implantation
- Where
- Japan
- Sponsor
- Nagoya University
Critical Limb Ischemia, Buerger Disease
Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
A prospective, open label, controlled, randomized, double arm, multi-center study to assess the efficacy and safety of CLBS12 in patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) with a single…
- Conditions
- Critical Limb Ischemia, Buerger Disease, Thromboangiitis Obliterans, Atherosclerosis Obliterans
- Trial name
- NCT02501018
- Testing
- CLBS12, SOC
- Where
- 12 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Lisata Therapeutics, Inc.
Ischemia, Thromboangiitis Obliterans
Contrast Enhanced Ultrasound and Muscle
The primary objective of our work is to show that quantification of muscular microvascularisation evaluated by injection of contrast agent is different between chronic critical limb ischemia (before revascularization) and after…
- Trial name
- Echomuscle (NCT02128750)
- Testing
- contrast echographie with hexafluorur of sulfur
- Where
- France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Grenoble
Critical Limb Ischemia, Buerger's Disease
A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease
This is an open label, non-randomized, dose ranging study to evaluate the safety and efficacy of different doses of Stempeucel in critical limb ischemia patients.
- Trial name
- NCT01484574
- Testing
- Allogeneic Mesenchymal Stem Cells
- Where
- 10 sites in India
- Volunteers
- 90 people
- Sponsor
- Stempeutics Research Pvt Ltd
Telomere Length, Quality of Life
Subtle Energy Transmission and Tao Calligraphy Mindfulness in Telomere Length in Peripheral Blood Leukocytes
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Telomere Length in Peripheral Blood Leukocytes A Follow-up Pilot Study The goal of this Pilot clinical trial is to learn if a Subtle Energy…
- Trial name
- NCT06357663
- Testing
- Mindfulness practice with Calligraphy
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Sha Research Foundation
Buerger Disease, Raynaud Syndrome
Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease
The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease.
- Trial name
- BETOX (NCT05698979)
- Testing
- BOTOX INJECTION
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Toulouse
Thromboangiitis Obliterans, Atheromatous Arteritis
ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's Disease
Background: Buerger's disease (thromboangiitis obliterans or TAO) is a rare disease (1/ 10 000) characterized by the development of segmental thrombotic occlusions of the medium and small arteries of the extremities.
- Trial name
- ADDICTAO (NCT01064206)
- Where
- 16 sites in France
- Volunteers
- 224 people
- Sponsor
- University Hospital, Lille
Thromboangiitis Obliterans
Treatment of Thromboangiitis Obliterans (Buerguer's Disease) With Bosentan
This study assessed the effectiveness and safety of bosentan when administered to thromboangiitis obliterans (Buerger's disease)patients.
- Trial name
- NCT01447550
- Testing
- Bosentan
- Where
- 2 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Hospital Universitario Getafe